



Supplementary material

Pooled Analysis of Two Randomized Trials Comparing Titanium-nitride-oxide-coated Stent Versus Drug-eluting Stent in ST Elevation Myocardial Infarction

Petri O. Tuomainen,^{a,b} Jussi Sia,^c Wail Nammas,^b Matti Niemelä,^d
Juhani K.E. Airaksinen,^e Fausto Biancari,^f and Pasi P. Karjalainen^{b,*}

^a*Department of Internal Medicine and Heart Center, Kuopio University Hospital, University of Eastern Finland, Kuopio, Finland*

^b*Department of Cardiology, Satakunta Central Hospital, Pori, Finland*

^c*Department of Cardiology, Kokkola Central Hospital, Kokkola, Finland*

^d*Department of Internal Medicine, Division of Cardiology, University of Oulu, Oulu, Finland*

^e*Department of Medicine, Turku University Hospital, Turku, Finland*

^f*Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Oulu, Finland*

Table 1

Baseline Clinical Characteristics of the Two Study Groups in the TITAX-AMI Trial

Variable	BAS group N=83	DES group N=97	P Value
Age, mean (SD), y	63.3 (10.5)	62.0 (11.8)	.43
Male gender	60 (72.3)	77 (79.4)	.27
Family history of CAD	36 (43.4)	47 (48.5)	.50
Diabetes mellitus	12 (14.5)	9 (9.3)	.28
Hypertension	41 (49.4)	45 (46.4)	.69
Hypercholesterolemia	47 (56.6)	68 (70.1)	.06
Current smoking	27 (32.5)	43 (44.3)	.11
Prior MI	10 (12.0)	6 (6.2)	.17
Prior PCI	4 (4.8)	4 (4.1)	.82
Prior CABG	4 (4.8)	0 (0)	.03
Prior stroke	1 (1.2)	4 (4.1)	.23

BAS, bioactive stent; DES, drug-eluting stent; CABG, coronary artery bypass grafting; CAD indicates coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation.

Continuous variables are presented as mean (standard deviation), while categorical variables are presented as frequency (percentage).

Table 2

Baseline Clinical Characteristics of the Two Study Groups in the BASE-ACS Trial

Variable	BAS group N=162	DES group N=159	P Value
Age, mean (SD), y	61.9 (12.0)	61.5 (12.5)	.79
Male gender	128 (79.0)	121 (76.1)	.53
Family history of CAD	75 (46.3)	60 (37.7)	.12
Diabetes mellitus	23 (14.2)	24 (15.1)	.82
Hypertension	54 (33.3)	61 (38.4)	.35
Hypercholesterolemia	50 (30.9)	55 (34.6)	.48
Current smoking	73 (45.1)	66 (41.5)	.52
Prior MI	13 (8.0)	8 (5.0)	.28
Prior PCI	5 (3.1)	12 (7.5)	.07
Prior CABG	5 (3.1)	2 (1.3)	.26
Prior stroke	5 (3.1)	2 (1.3)	.26

BAS, bioactive stent; DES, drug-eluting stent; CABG, coronary artery bypass grafting; CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation.

Continuous variables are presented as mean (SD), while categorical variables are presented as frequency (percentage).

Table 3

Angiographic and Procedural Data of the Two Study Groups in the TITAX-AMI Trial

Variable	BAS group N=83	DES group N=97	P Value
<i>Vessel type</i>			
Left anterior descending artery	49 (59.0)	39 (40.2)	.01
Left circumflex artery	4 (4.8)	21 (21.6)	.001
Right coronary artery	28 (33.7)	36 (37.1)	.64
Left main coronary artery	0 (0)	1 (1.0)	.35
Saphenous venous graft	2 (2.4)	0 (0)	.12
<i>Thrombus</i>	56 (67.5)	38 (39.2)	<.001
<i>Reference vessel diameter, mean (SD), mm</i>	3.26 (0.44)	3.20 (0.47)	.52
<i>Lesion length, mean (SD) mm</i>	14.3 (5.5)	12.5 (5.3)	.01
<i>Stent diameter, mean (SD), mm</i>	3.38 (1.15)	3.17 (0.44)	.10
<i>Stent length, mean (SD), mm</i>	18.1 (4.5)	17.4 (4.9)	.23
<i>Total stent length, mean (SD), mm</i>	19.3 (6.5)	17.9 (6.0)	.14
<i>Number of stents per culprit lesion, mean (SD)</i>	1.11 (0.31)	1.06 (0.28)	.30
<i>Thrombus aspiration</i>	0 (0)	0 (0)	NA
<i>Direct stenting</i>	11 (13.3)	18 (18.6)	.33
<i>Post-dilatation</i>	40 (48.2)	38 (39.2)	.22
<i>Medications</i>			
Low-molecular weight heparin	81 (97.6)	92 (94.8)	.34
Unfractionated heparin	1 (1.2)	1 (1.0)	.91
Glycoprotein IIb/IIIa inhibitor	55 (66.3)	56 (57.7)	.24
Bivalirudin	1 (1.2)	2 (2.1)	.65

BAS, bioactive stent; DES, drug-eluting stent; NA, not available; SD, standard deviation.

Continuous variables are presented as mean (standard deviation), while categorical variables are presented as frequency (percentage).

Table 4

Angiographic and Procedural Data of the Two Study Groups in the BASE-ACS Trial

Variable	BAS group N=162	DES group N=159	P Value
<i>Vessel type</i>			
Left anterior descending artery	66 (40.7)	79 (49.7)	.11
Left circumflex artery	27 (16.7)	30 (18.9)	.61
Right coronary artery	68 (42.0)	50 (31.4)	.05
Left main coronary artery	0 (0)	0 (0)	NA
Saphenous venous graft	1 (0.6)	0 (0)	.32
<i>Thrombus</i>	125 (77.2)	114 (71.7)	.26
<i>Reference vessel diameter, mean (SD), mm</i>	3.11 (0.40)	3.13 (0.41)	.57
<i>Lesion length, mean (SD), mm</i>	14.7 (5.0)	15.0 (7.4)	.72
<i>Stent diameter, mean (SD), mm</i>	3.13 (0.40)	3.14 (0.41)	.89
<i>Stent length, mean (SD), mm</i>	18.5 (5.0)	18.7 (5.4)	.72
<i>Total stent length, mean (SD), mm</i>	22.2 (10.2)	20.4 (7.6)	.14
<i>Number of stents per culprit lesion, mean (SD)</i>	1.17 (0.41)	1.13 (0.33)	.44
<i>Thrombus aspiration</i>	71 (43.8)	66 (41.5)	.67
<i>Direct stenting</i>	73 (45.1)	67 (42.1)	.60
<i>Post-dilatation</i>	65 (40.1)	70 (44.0)	.48
<i>Medications</i>			
Low-molecular weight heparin	68 (42.0)	62 (39.0)	.59
Unfractionated heparin	39 (24.1)	50 (31.4)	.14
Glycoprotein IIb/IIIa inhibitor	64 (39.5)	67 (42.1)	.63
Bivalirudin	54 (33.3)	46 (28.9)	.39

BAS, bioactive stent; DES, drug-eluting stent; NA, not available; SD, standard deviation.

Continuous variables are presented as mean (standard deviation), while categorical variables are presented as frequency (percentage).